Latest Regulatory Approvals News

Aristocrat Leisure Limited has announced an ordinary unfranked dividend of AUD 0.44 per share for the six months ending March 2025, with key dates set for May and July.

Highfield Resources has inked a non-binding letter of intent with Qinghai Salt Lake, a China Minmetals subsidiary, for a US$300 million equity investment aimed at fast-tracking its potash projects in Spain and Canada.

Ramelius Resources has obtained regulatory relief from ASIC, extending the deadline to make its takeover offer for Spartan Resources by an additional 31 days, a move that could influence the pace and outcome of the acquisition.

OM Holdings has agreed to sell its 26% interest in Ntsimbintle Mining to Exxaro Resources for US$101.4 million, marking a strategic shift to refocus capital on core operations while maintaining a commercial partnership.

Neuren Pharmaceuticals has received official FDA minutes confirming the primary endpoints for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, reinforcing the positive signals from earlier studies.

Peninsula Energy has received critical regulatory approvals for its Kendrick Project in Wyoming, paving the way for uranium recovery operations and advancing its broader Lance Projects development strategy.

Aguia Resources has secured key contracts and financing steps for its Tres Estradas phosphate project in Brazil, aiming for production start by late 2025 and first sales in early 2026.

Marvel Gold Limited has made significant progress in acquiring the Hanang Gold Project in Tanzania, submitting all regulatory documents and anticipating approvals soon. The company also prepares for its Annual General Meeting where shareholders will vote on a $2.5 million capital raising placement.

DMC Mining Limited has issued its Third Supplementary Prospectus, extending key deadlines for its Public Offer and loan repayment as exploration permits for its Guinean projects remain pending.

PolyNovo has secured Therapeutic Goods Administration clearance for thicker versions of its NovoSorb MTX product, broadening treatment options for complex wounds in Australia.

Bio-Gene Technology Limited has launched a Share Purchase Plan allowing Australian shareholders to invest up to $15,000 at 2.3 cents per share, matching a recent $2.1 million placement. The offer includes free-attaching options, subject to shareholder approval, to support key product development milestones.

Cleo Diagnostics has completed alpha testing of its ovarian cancer pre-surgical triage assay kits, confirming robust performance and differentiation between benign and malignant disease. The company now moves forward to assay optimisation and manufacturing scale-up, edging closer to FDA submission and commercial launch.